Joinn Laboratories(China)Co.,Ltd. (603127.SS)
CNY 17.42
(0.87%)
CNY 17.42
(0.87%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 1.01 Billion CNY | -10.61% |
| 2022 | 1.08 Billion CNY | 46.97% |
| 2021 | 739.12 Million CNY | 33.7% |
| 2020 | 552.81 Million CNY | 64.25% |
| 2019 | 336.56 Million CNY | 55.28% |
| 2018 | 216.74 Million CNY | 27.86% |
| 2017 | 169.52 Million CNY | 38.94% |
| 2016 | 122.01 Million CNY | 14.59% |
| 2015 | 106.47 Million CNY | 8.31% |
| 2014 | 98.3 Million CNY | 35.52% |
| 2013 | 72.53 Million CNY | 52.5% |
| 2012 | 47.56 Million CNY | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | 104.28 Million CNY | -66.11% |
| 2024 Q3 | 107.46 Million CNY | -28.97% |
| 2024 Q2 | 151.28 Million CNY | 45.07% |
| 2023 Q4 | 307.74 Million CNY | 25.07% |
| 2023 FY | 971.08 Million CNY | -10.61% |
| 2023 Q1 | 190.95 Million CNY | -57.74% |
| 2023 Q2 | 257.61 Million CNY | 34.91% |
| 2023 Q3 | 246.05 Million CNY | -4.49% |
| 2022 Q3 | 254 Million CNY | 5.68% |
| 2022 Q2 | 240.34 Million CNY | 71.6% |
| 2022 Q1 | 140.06 Million CNY | -55.29% |
| 2022 FY | 1.08 Billion CNY | 46.97% |
| 2022 Q4 | 451.89 Million CNY | 77.91% |
| 2021 Q1 | 103.66 Million CNY | -56.53% |
| 2021 Q3 | 154.58 Million CNY | -7.79% |
| 2021 Q4 | 313.22 Million CNY | 102.62% |
| 2021 FY | 739.12 Million CNY | 33.7% |
| 2021 Q2 | 167.64 Million CNY | 61.72% |
| 2020 Q3 | 115.03 Million CNY | -6.7% |
| 2020 Q4 | 238.44 Million CNY | 107.28% |
| 2020 FY | 552.81 Million CNY | 64.25% |
| 2020 Q1 | 76.03 Million CNY | -51.54% |
| 2020 Q2 | 123.29 Million CNY | 62.15% |
| 2019 FY | 336.56 Million CNY | 55.28% |
| 2019 Q4 | 156.89 Million CNY | 102.65% |
| 2019 Q3 | 77.42 Million CNY | 22.78% |
| 2019 Q2 | 63.05 Million CNY | 60.89% |
| 2019 Q1 | 39.19 Million CNY | -54.87% |
| 2018 Q3 | 60.56 Million CNY | 47.47% |
| 2018 Q2 | 41.06 Million CNY | 45.23% |
| 2018 Q4 | 86.83 Million CNY | 43.38% |
| 2018 Q1 | 28.27 Million CNY | -61.51% |
| 2018 FY | 216.74 Million CNY | 27.86% |
| 2017 FY | 169.52 Million CNY | 38.94% |
| 2017 Q1 | 9.06 Million CNY | -85.85% |
| 2017 Q2 | 41.91 Million CNY | 362.35% |
| 2017 Q3 | 45.07 Million CNY | 7.52% |
| 2017 Q4 | 73.46 Million CNY | 63.0% |
| 2016 Q3 | 22.96 Million CNY | 0.0% |
| 2016 Q4 | 64.05 Million CNY | 178.9% |
| 2016 FY | 122.01 Million CNY | 14.59% |
| 2015 FY | 106.47 Million CNY | 8.31% |
| 2014 FY | 98.3 Million CNY | 35.52% |
| 2013 FY | 72.53 Million CNY | 52.5% |
| 2012 FY | 47.56 Million CNY | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Shanghai Runda Medical Technology Co., Ltd. | 2.41 Billion CNY | 58.125% |
| WuXi AppTec Co., Ltd. | 16.27 Billion CNY | 93.778% |
| Autobio Diagnostics Co., Ltd. | 2.83 Billion CNY | 64.236% |
| Thalys Medical Technology Group Inc. | 389.73 Million CNY | -159.865% |
| Guangzhou Kingmed Diagnostics Group Co., Ltd. | 3.11 Billion CNY | 67.488% |
| Chemclin Diagnostics Co., Ltd. | 335.61 Million CNY | -201.768% |